Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Pediatr Hematol Oncol ; 42(8): e795-e797, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-30951019

RESUMEN

Langerhans cell histiocytosis (LCH) often has a recurrent and refractory course despite multiagent treatment modalities. Common relapse treatments include intense or prolonged cytotoxic chemotherapy regimens. There are a few prior reports that the nonsteroidal anti-inflammatory drug indomethacin demonstrated activity against bone LCH. Here we report indomethacin as a successful treatment for a case of chronic skin LCH that failed multiple prior chemotherapy regimens. This experience supports the need for trials to investigate indomethacin as a treatment for LCH both in the relapsed or refractory setting as well as potential combination or maintenance therapy in newly diagnosed patients.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Histiocitosis de Células de Langerhans/tratamiento farmacológico , Indometacina/uso terapéutico , Enfermedades de la Piel/tratamiento farmacológico , Niño , Histiocitosis de Células de Langerhans/patología , Humanos , Masculino , Pronóstico , Recurrencia , Enfermedades de la Piel/patología
2.
Pediatr Blood Cancer ; 60(8): 1320-4, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23519908

RESUMEN

BACKGROUND: Chemotherapy medication errors occur in all cancer treatment programs. Such errors have potential severe consequences: either enhanced toxicity or impaired disease control. Understanding and limiting chemotherapy errors are imperative. PROCEDURE: A multi-disciplinary team developed and implemented a prospective pharmacy surveillance system of chemotherapy prescribing and administration errors from 2008 to 2011 at a Children's Oncology Group-affiliated, pediatric cancer treatment program. Every chemotherapy order was prospectively reviewed for errors at the time of order submission. All chemotherapy errors were graded using standard error severity codes. Error rates were calculated by number of patient encounters and chemotherapy doses dispensed. Process improvement was utilized to develop techniques to minimize errors with a goal of zero errors reaching the patient. RESULTS: Over the duration of the study, more than 20,000 chemotherapy orders were reviewed. Error rates were low (6/1,000 patient encounters and 3.9/1,000 medications dispensed) at the start of the project and reduced by 50% to 3/1,000 patient encounters and 1.8/1,000 medications dispensed during the initiative. Error types included chemotherapy dosing or prescribing errors (42% of errors), treatment roadmap errors (26%), supportive care errors (15%), timing errors (12%), and pharmacy dispensing errors (4%). Ninety-two percent of errors were intercepted before reaching the patient. No error caused identified patient harm. Efforts to lower rates were successful but have not succeeded in preventing all errors. CONCLUSIONS: Chemotherapy medication errors are possibly unavoidable, but can be minimized by thoughtful, multispecialty review of current policies and procedures. Pediatr Blood Cancer 2013;601320-1324. © 2013 Wiley Periodicals, Inc.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Errores de Medicación/prevención & control , Neoplasias/dietoterapia , Adolescente , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Errores de Medicación/estadística & datos numéricos , Estudios Prospectivos
3.
Res Sq ; 2023 Oct 18.
Artículo en Inglés | MEDLINE | ID: mdl-37886476

RESUMEN

Hemophilia-A (HA) is caused by heterogeneous loss-of-function factor (F)VIII gene (F8)-mutations and deficiencies in plasma-FVIII-activity that impair intrinsic-pathway-mediated coagulation-amplification. The standard-of-care for severe-HA-patients is regular infusions of therapeutic-FVIII-proteins (tFVIIIs) but ~30% develop neutralizing-tFVIII-antibodies called "FVIII-inhibitors (FEIs)" and become refractory. We used the PATH study and ImmunoChip to scan immune-mediated-disease (IMD)-genes for novel and/or replicated genomic-sequence-variations associated with baseline-FEI-status while accounting for non-independence of data due to genetic-relatedness and F8-mutational-heterogeneity. The baseline-FEI-status of 450 North American PATH subjects-206 with black-African-ancestry and 244 with white-European-ancestry-was the dependent variable. The F8-mutation-data and a genetic-relatedness matrix were incorporated into a binary linear-mixed model of genetic association with baseline-FEI-status. We adopted a gene-centric-association-strategy to scan, as candidates, pleiotropic-IMD-genes implicated in the development of either ³2 autoimmune-/autoinflammatory-disorders (AADs) or ³1 AAD and FEIs. Baseline-FEI-status was significantly associated with SNPs assigned to NOS2A (rs117382854; p=3.2E-6) and B3GNT2 (rs10176009; p=5.1E-6), which have functions in anti-microbial-/-tumoral-immunity. Among IMD-genes implicated in FEI-risk previously, we identified strong associations with CTLA4 assigned SNPs (p=2.2E-5). The F8-mutation-effect underlies ~15% of the total heritability for baseline-FEI-status. Additive genetic heritability and SNPs in IMD-genes account for >50% of the patient-specific variability in baseline-FEI-status. Race is a significant determinant independent of F8-mutation-effects and non-F8-genetics.

4.
Cancer ; 118(7): 1919-24, 2012 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-21882180

RESUMEN

BACKGROUND: The widespread use of anthracycline chemotherapy has contributed to improved outcomes in children with cancer. The most feared complication of the anthracyclines is cardiotoxicity. Routine echocardiographic monitoring typically is used before, during, and after treatment to minimize cardiotoxicity. The ideal use of screening before and during chemotherapy remains uncertain. METHODS: This was a retrospective review of children who were treated at a single cancer treatment center over 5 years. The results of all echocardiograms and related clinical decisions were reviewed. RESULTS: In 356 patients who were identified for review (age range, 3 months to 22 years; mean age, 10 years; median age, 11 years), 991 echocardiograms were reviewed (average, 2.78 echocardiograms per patient; median, 2 echocardiograms per patient; mode, 1; maximum, 11 echocardiograms per patient). Nine abnormal echocardiograms were identified (2.5% of patients and 0.9% of echocardiograms performed). Four echocardiograms were performed during episodes of septic shock, 2 echocardiograms represented false-positive studies after repeat evaluation, and 1 echocardiogram demonstrated mild abnormality of function on the day of surgical resection of a large Wilms tumor. None of the 356 pretreatment echocardiograms altered treatment decisions. In 635 follow-up echocardiograms during treatment, cardiac defects were detected in 2 patients (0.5%). CONCLUSIONS: The routine use of echocardiograms to screen for anthracycline-induced cardiac damage before and during chemotherapy rarely identified significant cardiac damage to impact treatment decisions. Improved screening techniques with better discrimination and predictability are needed. Pediatric Oncology cooperative groups should consider a revision of standard monitoring protocols before and during treatment.


Asunto(s)
Antraciclinas/efectos adversos , Antineoplásicos/efectos adversos , Ecocardiografía/métodos , Cardiopatías/inducido químicamente , Monitoreo Fisiológico , Adolescente , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Estudios Retrospectivos , Adulto Joven
5.
N Engl J Med ; 360(16): 1618-27, 2009 Apr 16.
Artículo en Inglés | MEDLINE | ID: mdl-19369668

RESUMEN

BACKGROUND: Black patients with hemophilia A (factor VIII deficiency) are twice as likely as white patients to produce inhibitors against factor VIII proteins given as replacement therapy. There are six wild-type factor VIII proteins, designated H1 through H6, but only two (H1 and H2) match the recombinant factor VIII products used clinically. H1 and H2 are found in all racial groups and are the only factor VIII proteins found in the white population to date. H3, H4, and H5 have been found only in blacks. We hypothesized that mismatched factor VIII transfusions contribute to the high incidence of inhibitors among black patients. METHODS: We sequenced the factor VIII gene (F8) in black patients with hemophilia A to identify causative mutations and the background haplotypes on which they reside. Results from previous Bethesda assays and information on the baseline severity of hemophilia, age at enrollment, and biologic relationships among study patients were obtained from review of the patients' medical charts. We used multivariable logistic regression to control for these potential confounders while testing for associations between F8 haplotype and the development of inhibitors. RESULTS: Of the 78 black patients with hemophilia enrolled, 24% had an H3 or H4 background haplotype. The prevalence of inhibitors was higher among patients with either of these haplotypes than among patients with haplotype H1 or H2 (odds ratio, 3.6; 95% confidence interval, 1.1 to 12.3; P=0.04), despite a similar spectrum of hemophilic mutations and degree of severity of illness in these two subgroups. CONCLUSIONS: These preliminary results suggest that mismatched factor VIII replacement therapy may be a risk factor for the development of anti-factor VIII alloantibodies.


Asunto(s)
Población Negra/genética , Inhibidores de Factor de Coagulación Sanguínea/inmunología , Factor VIII/genética , Factor VIII/inmunología , Hemofilia A/etnología , Hemofilia A/inmunología , Adolescente , Adulto , Secuencia de Aminoácidos , Anticuerpos , Inhibidores de Factor de Coagulación Sanguínea/genética , Niño , Preescolar , Factor VIII/uso terapéutico , Haplotipos , Hemofilia A/genética , Hemofilia A/terapia , Humanos , Isoanticuerpos , Masculino , Mutación , Polimorfismo de Nucleótido Simple , Factores de Riesgo , Adulto Joven
6.
J Pediatr Hematol Oncol ; 33(4): 261-4, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21516021

RESUMEN

Venous thrombosis is an infrequent but serious cause of hospitalization in children. The epidemiology and natural history remains incompletely defined, especially in geographically distinct regions of the United States. We thus evaluated thrombosis in a single children's hospital over a 3-year period. Of 41,906 hospitalizations, 92 children were identified for review. The incidence of thrombosis was 21.9 per 10,000 admissions (0.22%). Venous thrombosis was of equal incidence in African-American and white patients. Locations of thrombosis included deep venous (51%), pulmonary (21%), renal vein (8%), intrahepatic (8%), and intracranial (12%). Risk factors for thrombosis included central catheter (32%), malignancy (18%), systemic infection (21%), neurologic disability (9%), cardiac (4%), nephrotic syndrome (3%), and autoimmune (6%). Six of 92 patients (7%) had thrombophilia. Positive family history of venous thromboembolism (VTE) or thrombophilic disorder predicted an abnormal test. Treatment included low-molecular-weight heparin (n=53), coumadin (n=12), heparin (n=10), tissue plasminogen activator (n=6), argatroban (n=1), thrombectomy (n=2), inferior vena cava filter (n=2), and no treatment (n=23). Seventy-seven percent demonstrated resolution of the VTE, 14% had persistent or recurrent VTE, and 9% died. Causes of death were malignancy, prematurity, septicemia, and congenital heart disease. Venous thrombosis is a serious comorbidity in hospitalized children. In our population, African-Americans had an equal incidence of VTE as whites. Positive family history predicted thrombophilia.


Asunto(s)
Centros Médicos Académicos/estadística & datos numéricos , Negro o Afroamericano/estadística & datos numéricos , Hospitales Pediátricos/estadística & datos numéricos , Tromboembolia Venosa/etnología , Población Blanca/estadística & datos numéricos , Adolescente , Alabama/epidemiología , Venas Cerebrales , Niño , Preescolar , Comorbilidad , Femenino , Venas Hepáticas , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Venas Pulmonares , Venas Renales , Factores de Riesgo , Adulto Joven
7.
Pediatr Emerg Care ; 24(12): 839-41, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19092562

RESUMEN

Intramuscular venous malformations are uncommon benign masses of vascular origin that can occur anywhere in the body. They can be small and clinically insignificant or can be large and violate tissue planes and viscera. Presentation is as variable as the extent of the lesions. They can be diagnosed as a result of local pain and swelling or as incidental findings. Rarely, venous malformations can get infected and present with fever or other more severe systemic symptoms. The literature is sparse regarding infection of intramuscular venous malformations. This case describes the presentation, diagnosis, and management of a patient with group A streptococcal infection of a previously undiagnosed intramuscularvenous malformation in a patient who presented to our pediatric emergency department.


Asunto(s)
Hemangioma Cavernoso/diagnóstico , Neoplasias de los Músculos/diagnóstico , Músculo Esquelético/irrigación sanguínea , Miositis/etiología , Infecciones Estreptocócicas/etiología , Streptococcus pyogenes/aislamiento & purificación , Biopsia , Calcinosis/diagnóstico por imagen , Calcinosis/etiología , Preescolar , Clindamicina/uso terapéutico , Terapia Combinada , Diagnóstico Diferencial , Quimioterapia Combinada , Fiebre/etiología , Hemangioma Cavernoso/complicaciones , Hemangioma Cavernoso/diagnóstico por imagen , Hemangioma Cavernoso/patología , Hemangiosarcoma/diagnóstico , Humanos , Masculino , Neoplasias de los Músculos/complicaciones , Neoplasias de los Músculos/diagnóstico por imagen , Neoplasias de los Músculos/patología , Músculo Esquelético/diagnóstico por imagen , Músculo Esquelético/patología , Miositis/diagnóstico por imagen , Miositis/tratamiento farmacológico , Miositis/microbiología , Miositis/cirugía , Rabdomiosarcoma/diagnóstico , Infecciones Estreptocócicas/diagnóstico por imagen , Infecciones Estreptocócicas/tratamiento farmacológico , Infecciones Estreptocócicas/cirugía , Tomografía Computarizada por Rayos X , Vancomicina/uso terapéutico
8.
Sci Rep ; 7(1): 17787, 2017 12 19.
Artículo en Inglés | MEDLINE | ID: mdl-29259192

RESUMEN

Neuroblastoma is a pediatric tumor characterized by histologic heterogeneity, and accounts for ~15% of childhood deaths from cancer. The five-year survival for patients with high-risk stage 4 disease has not improved in two decades. We used whole exome sequencing (WES) to identify mutations present in three independent high-risk stage 4 neuroblastoma tumors (COA/UAB-3, COA/UAB -6 and COA/UAB -8) and a stage 3 tumor (COA/UAB-14). Among the four tumors WES analysis identified forty-three mutations that had not been reported previously, one of which was present in two of the four tumors. WES analysis also corroborated twenty-two mutations that were reported previously. No single mutation occurred in all four tumors or in all stage 4 tumors. Three of the four tumors harbored genes with CADD scores ≥20, indicative of mutations associated with human pathologies. The average depth of coverage ranged from 39.68 to 90.27, with >99% sequences mapping to the genome. In summary, WES identified sixty-five coding mutations including forty-three mutations not reported previously in primary neuroblastoma tumors. The three stage 4 tumors contained mutations in genes encoding protein products that regulate immune function or cell adhesion and tumor cell metastasis.


Asunto(s)
Exoma/genética , Mutación/genética , Neuroblastoma/genética , Adhesión Celular/genética , Femenino , Humanos , Lactante , Masculino , Metástasis de la Neoplasia/genética , Secuenciación del Exoma/métodos
9.
Front Oncol ; 7: 327, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29376028

RESUMEN

Therapy for rhabdomyosarcoma (RMS) has generally been limited to combinations of conventional cytotoxic agents similar to regimens originally developed in the late 1960s. Recently, identification of molecular alterations through next-generation sequencing of individual tumor specimens has facilitated the use of more targeted therapeutic approaches for various malignancies. Such targeted therapies have revolutionized treatment for some cancer types. However, malignancies common in children, thus far, have been less amenable to such targeted therapies. This report describes the clinical course of an 8-year-old female with embryonal RMS having anaplastic features. This patient experienced multiple relapses after receiving various established and experimental therapies. Genomic testing of this RMS subtype revealed mutations in BCOR, ARID1A, and SETD2 genes, each of which contributes to epigenetic regulation and interacts with or modifies the activity of histone deacetylases (HDAC). Based on these findings, the patient was treated with the HDAC inhibitor vorinostat as a single agent. The tumor responded transiently followed by subsequent disease progression. We also examined the efficacy of vorinostat in a patient-derived xenograft (PDX) model developed using tumor tissue obtained from the patient's most recent tumor resection. The antitumor activity of vorinostat observed with the PDX model reflected clinical observations in that obvious areas of tumor necrosis were evident following exposure to vorinostat. Histologic sections of tumors harvested from PDX tumor-bearing mice treated with vorinostat demonstrated induction of necrosis by this agent. We propose that the evaluation of clinical efficacy in this type of preclinical model merits further evaluation to determine if PDX models predict tumor sensitivity to specific agents and/or combination therapies.

10.
Pediatr Crit Care Med ; 6(3): 352-4, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-15857538

RESUMEN

OBJECTIVE: To present a case report of a patient with Noonan syndrome who developed life-threatening gastrointestinal bleeding shortly after cardiac surgery that was successfully treated with recombinant factor VIIa. DESIGN: Case report. SETTING: Pediatric intensive care unit of a children's hospital. PATIENT: Ten-month-old with Noonan syndrome and massive gastrointestinal bleeding resulting in severe hypovolemic shock. INTERVENTIONS: Recombinant factor VIIa was used in this patient's severe bleeding associated with Noonan syndrome after no other supportive measures were successful. MEASUREMENTS AND MAIN RESULTS: Recombinant Factor VIIa significantly decreased the patient's bleeding and allowed his hypovolemic shock to improve. Ultimately, the patient made a complete recovery. CONCLUSIONS: Noonan syndrome has a constellation of both cardiac and noncardiac malformations including an increased risk of bleeding, and recombinant factor VIIa is an important agent in the treatment of significant bleeding.


Asunto(s)
Factor VII/uso terapéutico , Hemorragia Gastrointestinal/tratamiento farmacológico , Hemostáticos/uso terapéutico , Síndrome de Noonan/cirugía , Hemorragia Posoperatoria/tratamiento farmacológico , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Factor VIIa , Hemorragia Gastrointestinal/etiología , Humanos , Lactante , Unidades de Cuidado Intensivo Pediátrico , Masculino , Síndrome de Noonan/complicaciones , Proteínas Recombinantes/uso terapéutico
11.
Clin Pediatr (Phila) ; 43(8): 691-702, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15494875

RESUMEN

Childhood idiopathic thrombocytopenic purpura (ITP) is a common disorder. However, single-institution, long-term, natural history data are limited. The objective of this paper is to review presenting features, response to therapy, and natural history of ITP treated at a single pediatric academic medical center. A retrospective chart review was made for all children (ages birth-18 years) diagnosed with ITP (ICD 287.3) and treated at the Childrens Hospital of Alabama/University of Alabama at Birmingham between 1993 and 2003. Four hundred nine patients were identified (49% male, 51% female; mean age: 5.85 years; range: 1 month-17 years). There was no seasonal variation of presentation. The mean platelet count was 19k (0-120k). Bone marrow aspiration (BMA) was performed in 72% but altered the diagnosis or therapy in no patient. Treatment consisted of corticosteroids in 256 (92% response), intravenous immunoglobulin (IVIG) in 125 (87% response), Win-Rho D in 58 (91% response), and no therapy in 71 (100% response). Response was defined as increase in platelet count to > 50k. There was no difference in response to any therapy. No patients died. One patient presented with a CNS hemorrhage at presentation, responded to therapy, and survived. Twenty-three of 409 patients (6%) experienced clinical bleeding requiring hospitalization or blood transfusion. Chronic ITP (persistence > 6 months) was noted in 99 patients (24%). Chronic patients presented at an older age (7.8 vs 5.2 years for acute only, p<0.001), and with higher platelet counts (27k vs 17k, p<0.001). The risk of chronic ITP was partially predicted by presenting platelet count > 50k and age > 10 years, or both; 50% of patients presenting with these features developed chronic ITP vs 24% overall rate. Splenectomy was curative in 30/31 (97%) patients. There was no postsplenectomy sepsis. Of 99 patients with chronic ITP, 25 responded to splenectomy, 37 resolved at a mean of 20.3 months after diagnosis (7-96 months), 36 had persistent mild thrombocytopenia (50k-125k), and 1 failed to respond to any treatment including splenectomy. Overall, 91% of cases resolved with therapy or observation. ITP is a common pediatric disease presenting at any age with low morbidity and mortality. Most cases can be managed by pediatricians without hematology referral. Several equally successful therapeutic options exist. Chronic cases present at an older age with higher platelet counts. Up to 50% of cases of chronic ITP will resolve with ongoing follow-up. The overall prognosis in childhood ITP is excellent.


Asunto(s)
Púrpura Trombocitopénica Idiopática/terapia , Centros Médicos Académicos , Adolescente , Alabama/epidemiología , Niño , Preescolar , Comorbilidad , Diagnóstico Diferencial , Femenino , Glucocorticoides/uso terapéutico , Hospitales Pediátricos , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Lactante , Recién Nacido , Infusiones Intravenosas , Masculino , Recuento de Plaquetas , Púrpura Trombocitopénica Idiopática/complicaciones , Púrpura Trombocitopénica Idiopática/diagnóstico , Púrpura Trombocitopénica Idiopática/epidemiología , Estudios Retrospectivos , Globulina Inmune rho(D)/uso terapéutico
12.
PLoS One ; 8(5): e61120, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23667433

RESUMEN

Evidence of antibody isotype/subtype switching may provide prognostic value regarding the state of immune responses to therapeutic proteins, e.g. anti-factor VIII (FVIII) antibodies that develop in many hemophilia A patients, clinically termed "inhibitors". A sensitive, high- information-content surface plasmon resonance (SPR) assay has been developed to quantify IgG subtype distributions and the domain specificity of anti-drug antibodies. Plasma samples from 22 subjects with an allo- or auto-immune reaction to FVIII were analyzed. Pre-analytical treatment protocols were developed to minimize non-specific binding and specific matrix interference due to von Willebrand factor-FVIII interactions. The dynamic range for IgG quantification was 0.2-5 µg/ml (∼1-33 nM), allowing characterization of inhibitor-positive samples. Subtype-specific monoclonal antibodies were used to quantify the IgG subtype distribution of FVIII-specific antibodies. Most samples obtained from multiply-infused inhibitor subjects contained IgG4 antibodies. Several distinct phenotypes were assigned based on the IgG subtype distribution: IgG1, IgG4, IgG1 & IgG4, and IgG1, IgG2 & IgG4. An IgG1-only response was found in mild/moderate HA subjects during early FVIII infusions, and analysis of serial samples followed antibody class switching as several subjects' immune responses developed. Competition studies utilizing a recombinant FVIII-C2 domain indicated 40-80% of FVIII-specific antibodies in most samples were directed against this domain.


Asunto(s)
Formación de Anticuerpos/inmunología , Factor VIII/inmunología , Hemofilia A/inmunología , Inmunoglobulina G/inmunología , Fenotipo , Resonancia por Plasmón de Superficie/métodos , Animales , Anticuerpos Monoclonales/inmunología , Hemofilia A/sangre , Humanos , Inmunoglobulina G/clasificación , Ratones
13.
Clin Pediatr (Phila) ; 50(3): 225-30, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21098529

RESUMEN

Immune thrombocytopenic purpura (ITP) is the most common cause of thrombocytopenia in children and adolescents. However, there are a number of other diagnoses that are often mistaken for ITP. A 10-year retrospective chart review was performed at the Children's Hospital of Alabama to characterize ITP. Initially, 492 patients who had the coded diagnosis of ITP (ICD 287.3) were identified. However, 83 (17%) of patients were found to have alternative diagnoses on chart review. Of the 83 patients, 13 patients (3%) represented coding errors or study classification errors. The 70 remaining patients (14%) had an alternative explanation for their thrombocytopenia, consisting of 31 different diagnoses. The most common diagnoses were familial thrombocytopenia (10%), systemic lupus erythematosus (9%), hypersplenism (9%), neonatal alloimmune thrombocytopenia (7%), Wiskott-Aldrich syndrome (7%), or systemic infection (6%). In total, 16 of the patients (23%) were ultimately diagnosed with one of a number of congenital syndromes with concurrent thrombocytopenia. Although this review confirms that most children with thrombocytopenia are diagnosed with ITP, 14% of the study population manifested other diagnoses. The clinician evaluating a child with thrombocytopenia must keep an open mind about the possible diagnosis and perform a comprehensive and thoughtful evaluation based on the clinical picture. ITP must be a diagnosis of exclusion as misdiagnosis in a child with thrombocytopenia may have a significant impact on morbidity and mortality.


Asunto(s)
Púrpura Trombocitopénica Idiopática/diagnóstico , Trombocitopenia/diagnóstico , Trombocitopenia/etiología , Adolescente , Niño , Preescolar , Diagnóstico Diferencial , Femenino , Humanos , Lactante , Masculino , Estudios Retrospectivos , Síndrome
14.
Lancet Neurol ; 10(6): 509-19, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21565557

RESUMEN

BACKGROUND: Human retinal pigment epithelial (RPE) cells produce levodopa and their transplantation into the striatum might improve continuity of administration compared with that achieved with oral levodopa. We aimed to assess the safety, tolerability, and efficacy of transplantation of microcarrier-bound human RPE cells versus a sham surgery control in patients with advanced Parkinson's disease. METHODS: In this randomised, double-blind study eligible patients were aged 36-70 years, had been symptomatic for at least 5 years, were in Hoehn and Yahr stage 3-4 and had unified Parkinson's disease rating scale (UPDRS) motor scores of 38-70 when off medication (off state), and had symptoms that responded to oral levodopa but were insufficiently controlled by optimised pharmacotherapy. Randomisation was done in a 1:1 ratio. Only the neurosurgical team was aware of treatment assignments. During stereotactic transplantation around 325,000 cells per side were injected into the postcommissural putamen; sham surgery patients received partial burr holes. The primary efficacy endpoint was change in UPDRS off-state motor score at 12 months. This study is registered with ClinicalTrials.gov, number NCT00206687. FINDINGS: Of 71 enrolled patients, 35 underwent cell transplantation and 36 sham surgery. Change in mean motor scores did not differ significantly between groups (-10.5 [SD 10.26] for transplantation vs -10.1 [SD 12.26] for sham surgery, p=0.9). The overall rate of adverse events was similar in the two study groups, although the number attributable to surgery or RPE cells (mostly neurological or psychiatric) was higher in transplant recipients. Two and seven patients died in the sham surgery and transplantation group, respectively; one death in the latter group was possibly related to surgery or RPE cells. INTERPRETATION: Transplantation of human RPE cells provided no antiparkinsonian benefits compared with sham surgery. FUNDING: Bayer HealthCare AG.


Asunto(s)
Cuerpo Estriado/cirugía , Portadores de Fármacos , Células Epiteliales/trasplante , Enfermedad de Parkinson/cirugía , Placebos/uso terapéutico , Epitelio Pigmentado de la Retina/citología , Adulto , Anciano , Método Doble Ciego , Células Epiteliales/citología , Células Epiteliales/metabolismo , Femenino , Humanos , Levodopa/metabolismo , Levodopa/uso terapéutico , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/patología , Enfermedad de Parkinson/fisiopatología , Resultado del Tratamiento
15.
Lancet Neurol ; 9(12): 1164-1172, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20970382

RESUMEN

BACKGROUND: In an open-label phase 1 trial, gene delivery of the trophic factor neurturin via an adeno-associated type-2 vector (AAV2) was well tolerated and seemed to improve motor function in patients with advanced Parkinson's disease. We aimed to assess the safety and efficacy of AAV2-neurturin in a double-blind, phase 2 randomised trial. METHODS: We did a multicentre, double-blind, sham-surgery controlled trial in patients with advanced Parkinson's disease. Patients were randomly assigned (2:1) by a central, computer generated, randomisation code to receive either AAV2-neurturin (5·4 × 10¹¹ vector genomes) injected bilaterally into the putamen or sham surgery. All patients and study personnel with the exception of the neurosurgical team were masked to treatment assignment. The primary endpoint was change from baseline to 12 months in the motor subscore of the unified Parkinson's disease rating scale in the practically-defined off state. All randomly assigned patients who had at least one assessment after baseline were included in the primary analyses. This trial is registered at ClinicalTrials.gov, NCT00400634. RESULTS: Between December, 2006, and November, 2008, 58 patients from nine sites in the USA participated in the trial. There was no significant difference in the primary endpoint in patients treated with AAV2-neurturin compared with control individuals (difference -0·31 [SE 2·63], 95% CI -5·58 to 4·97; p=0·91). Serious adverse events occurred in 13 of 38 patients treated with AAV2-neurturin and four of 20 control individuals. Three patients in the AAV2-neurturin group and two in the sham surgery group developed tumours. INTERPRETATION: Intraputaminal AAV2-neurturin is not superior to sham surgery when assessed using the UPDRS motor score at 12 months. However, the possibility of a benefit with additional targeting of the substantia nigra and longer term follow-up should be investigated in further studies. FUNDING: Ceregene and Michael J Fox Foundation for Parkinson's Research.


Asunto(s)
Dependovirus/fisiología , Terapia Genética/métodos , Neurturina/genética , Neurturina/uso terapéutico , Enfermedad de Parkinson/terapia , Adulto , Anciano , Análisis de Varianza , Dependovirus/genética , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Actividad Motora/fisiología , Neurturina/metabolismo , Enfermedad de Parkinson/genética , Enfermedad de Parkinson/fisiopatología , Putamen/metabolismo , Putamen/fisiología , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento
16.
Science ; 316(5825): 736-8, 2007 May 04.
Artículo en Inglés | MEDLINE | ID: mdl-17478718

RESUMEN

Roads encroaching into undeveloped areas generally degrade ecological and watershed conditions and simultaneously provide access to natural resources, land parcels for development, and recreation. A metric of roadless space is needed for monitoring the balance between these ecological costs and societal benefits. We introduce a metric, roadless volume (RV), which is derived from the calculated distance to the nearest road. RV is useful and integrable over scales ranging from local to national. The 2.1 million cubic kilometers of RV in the conterminous United States are distributed with extreme inhomogeneity among its counties.

18.
Am J Hematol ; 79(1): 58-60, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-15849767

RESUMEN

We report a patient with hemophilia A and high-titer factor VIII inhibitor who developed compartment syndrome of his forearm following trauma. Emergency fasciotomy was performed. Initial hemostatic treatment with factor VIII inhibitor bypassing activity (FEIBA) was unsuccessful. Bleeding was controlled with recombinant factor VIIa.


Asunto(s)
Factor VIII/antagonistas & inhibidores , Factor VIIa/uso terapéutico , Fasciotomía , Hemofilia A/tratamiento farmacológico , Autoanticuerpos/sangre , Niño , Urgencias Médicas , Hemofilia A/sangre , Hemofilia A/inmunología , Humanos , Masculino , Proteínas Recombinantes/uso terapéutico
19.
Am J Hematol ; 69(3): 223-4, 2002 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11891812

RESUMEN

A 3-year-old child presented with severe hyperphosphatemia (phosphate 45 mg/dL) secondary to chronic enema use. Following aggressive correction of the hyperphosphatemia, hypophosphatemia ensued (phosphate 1.7 mg/dL). Concurrently, the patient developed severe intravascular hemolysis and RBC morphologic defects. The hemolysis and morphologic defects corrected with return to normal serum phosphate levels. Severe hypophosphatemia is a rare cause of intravascular hemolysis.


Asunto(s)
Hemólisis , Hipofosfatemia/complicaciones , Anemia Hemolítica/sangre , Anemia Hemolítica/etiología , Preescolar , Enema/efectos adversos , Eritrocitos/patología , Hemólisis/fisiología , Humanos , Hipofosfatemia/sangre , Hipofosfatemia/etiología , Masculino , Fosfatos/sangre
20.
J Pediatr Hematol Oncol ; 24(8): 622-6, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12439033

RESUMEN

Posttransplant lymphoproliferative disorder is a clinical challenge. Traditional chemotherapy results in tumor response, but toxicity and transplant rejection limit survival. The authors treated seven patients with malignant lymphoma after organ transplant with chemotherapy tailored to individual patient response. Chemotherapy consisted of vincristine, cyclophosphamide, and prednisone, with or without doxorubicin (Adriamycin; Pharmacia & Upjohn, Peapack, NJ, U.S.A.), or the ProMACE-CytaBOM regimen. Six of seven patients (86%) showed a complete response to treatment, with five of seven (71%) alive disease-free at 9 to 72 months (mean 38.2) after treatment. The results show that chemotherapy tailored to individual patient response is a safe and effective therapy for malignant lymphoma arising in patients with posttransplant lymphoproliferative disorder.


Asunto(s)
Linfoma de Células B/tratamiento farmacológico , Trastornos Linfoproliferativos/etiología , Complicaciones Posoperatorias/tratamiento farmacológico , Algoritmos , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Bleomicina/administración & dosificación , Linfoma de Burkitt/tratamiento farmacológico , Linfoma de Burkitt/etiología , Quimioterapia Adyuvante , Niño , Preescolar , Ciclofosfamida/administración & dosificación , Citarabina/administración & dosificación , Doxorrubicina/administración & dosificación , Infecciones por Virus de Epstein-Barr , Etopósido/administración & dosificación , Resultado Fatal , Femenino , Trasplante de Corazón , Humanos , Terapia de Inmunosupresión/efectos adversos , Trasplante de Riñón , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/etiología , Linfoma Relacionado con SIDA/tratamiento farmacológico , Linfoma de Células B/etiología , Linfoma de Células B/mortalidad , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/etiología , Masculino , Metotrexato/administración & dosificación , Complicaciones Posoperatorias/etiología , Prednisona/administración & dosificación , Inducción de Remisión , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/etiología , Análisis de Supervivencia , Resultado del Tratamiento , Vincristina/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA